# US 2025/0093339 A1 · Compositions and methods for enhanced sample multiplexing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0093339 A1
- Document ID: US20250093339A1
- Status: Published application
- Kind: A1
- Application number: 18/718,336
- Filed: 2022-12-14
- Published: 2025-03-20
- Earliest claimed: 2021-12-15
- Assignees: Biolegend, Inc.
- Applicants: BioLegend, Inc.
- Inventors: Andre VIEIRA ZORZETTO FERNANDES; Ze SHI; Zeinab MOUSSA; Fernando GRIGERA
- Web page: https://patentgrep.com/patent/US20250093339A1

## CPC

- C12Q 1/6816: characterised by the detection means (C12Q1/6804 takes precedence)
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- C12Q 1/6804: Nucleic acid analysis using immunogens (immunoassay G01N33/53)
- C12Q 1/6869: Methods for sequencing
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 2400/10: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N 2458/10: Oligonucleotides as tagging agents for labelling antibodies
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are compositions, methods and systems that allow for detection of samples via compositions that bind ubiquitous ligands or targets, to improve the capability of multi-sample utilization in single cell sequencing.

## Claims

### Claim at position 1

1-38. (canceled)

### Claim 39

A method comprising:
(a) contacting a plurality of target cells comprising one or more glycans with a first plurality of complexes, wherein:
the first plurality of complexes comprise a first glycan-binding agent and a first labeling oligonucleotide,
the first glycan-binding agent binds to all or a portion of a first glycan on the one or more target cells, and
the first glycan-binding agent is a first lectin;
(b) detecting the first labeling oligonucleotide; and
(c) identifying a first glycan on the one or more target cells according to the detection of the first labeling oligonucleotide.

### Claim 40 (depends on 39)

The method of claim 39, wherein first glycan-binding agent is linked to the first labeling oligonucleotide.

### Claim 41 (depends on 39)

The method of claim 39, wherein the first plurality of complexes further comprise biotin linked to the first glycan-binding agent and the first labeling oligonucleotide.

### Claim 42 (depends on 39)

The method of claim 39, wherein the first plurality of complexes further comprise (i) biotin linked to the first glycan-binding agent, and (ii) an anti-biotin antibody bound to the biotin and linked to the first labeling oligonucleotide.

### Claim 43 (depends on 39)

The method of claim 39, wherein the first plurality of complexes further comprise (i) biotin linked to the first glycan-binding agent, and (ii) streptavidin bound to the biotin and linked to the first labeling oligonucleotide.

### Claim 44 (depends on 39)

The method of claim 39, wherein first labeling oligonucleotide further comprises one or more of:
one or more detectable labels,
first barcode, wherein the first barcode is specific for the first glycan,
a binding site for a primer, and
a capture sequence.

### Claim 45 (depends on 44)

The method of claim 44, wherein the one or more detectable labels comprise one or more of radioisotopes, fluorophores, chemiluminescent compounds, bioluminescent compounds, and dyes.

### Claim 46 (depends on 44)

The method of claim 44, wherein the detecting in (b) comprises qualitative or quantitative detection of the one or more detectable labels.

### Claim 47 (depends on 39)

The method of claim 39, further comprising after (a) partitioning the plurality of target cells into a plurality of partitions, wherein each partition of the plurality of partitions comprises a single target cell associated with a first complex.

### Claim 48 (depends on 39)

The method of claim 39,
wherein (a) further comprises contacting the plurality of target cells with one or more additional pluralities of complexes, wherein:
the one or more additional plurality of complexes comprise one or more additional glycan-binding agents and one or more additional labeling oligonucleotides,
the one or more additional glycan-binding agents bind to all or a portion of one or more additional glycans on the one or more target cells, and
the one or more additional glycan-binding agents are one or more additional lectins;
wherein (b) further comprises detecting the one or more additional labeling oligonucleotides; and
wherein (c) further comprises identifying one or more additional glycans on the one or more target cells according to detection of the one or more additional labeling oligonucleotides.

### Claim 49 (depends on 48)

The method of claim 48, wherein the one or more additional glycan-binding agents are linked to the one or more additional labeling oligonucleotides.

### Claim 50 (depends on 48)

The method of claim 48, wherein the one or more additional pluralities of complexes further comprise biotin linked to the one or more additional glycan-binding agents and the one or more additional labeling oligonucleotides.

### Claim 51 (depends on 48)

The method of claim 48, wherein the one or more additional pluralities of complexes further comprise (i) biotin linked to the one or more additional glycan-binding agents, and (ii) an anti-biotin antibody bound to the biotin and linked to the one or more additional labeling oligonucleotides.

### Claim 52 (depends on 48)

The method of claim 48, wherein the one or more additional pluralities of complexes further comprise (i) biotin linked to the one or more additional glycan-binding agents, and (ii) streptavidin bound to the biotin and linked to the one or more additional labeling oligonucleotides.

### Claim 53 (depends on 48)

The method of claim 48, wherein the one or more additional labeling oligonucleotides further comprise one or more of:
one or more detectable labels,
one or more additional barcodes, wherein the one or more additional barcodes are specific for the one or more additional glycans,
a binding site for a primer, and
a capture sequence.

### Claim 54 (depends on 53)

The method of claim 53, wherein the one or more detectable labels comprise one or more of radioisotopes, fluorophores, chemiluminescent compounds, bioluminescent compounds, and dyes.

### Claim 55 (depends on 53)

The method of claim 53, wherein the detecting in (b) comprises qualitative or quantitative detection of the one or more detectable labels.

### Claim 56 (depends on 48)

The method of claim 48, further comprising after (a) partitioning the plurality of target cells into a plurality of partitions, wherein each partition of the plurality of partitions comprises a single target cell associated with the first complex or one of the additional complexes.

### Claim 57 (depends on 39)

The method of claim 39, wherein the detecting in (b) comprises sequencing.

### Claim 58 (depends on 39)

The method of claim 39, wherein the detecting in (b) comprises single cell sequencing.
